Actinic keratosis market

Actinic Keratosis is a damage caused to skin due to excessive sun exposure. Actinic Keratosis is a very common precursor to skin cancer. Actinic keratosis is considered a chronic disorder, where the majority of patients experience recurrent lesions over time. Actinic keratosis increases the risk of developing skin cancer, as it may develop into squamous cell carcinoma (SCC), a common and sometimes invasive skin cancer. Actinic keratosis is an early precursor to squamous cell carcinoma, a malignant skin tumor that develops from the keratinizing cells (keratinocytes) in the epidermis or skin adnexa. Due to the risk that actinic keratosis may develop into SCC, treatment is generally recommended. The disease is mainly treated repeatedly with cryotherapy, photodynamic therapy or topical agents.

Global Actinic Keratosis Market - Impact of the Coronavirus (COVID-19) Pandemic

COVID-19 Pandemic has impacted all the business sectors. Healthcare sector has also been impacted by the COVID-19. The coronavirus or COVID-19 outbreak started in Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. The economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others have been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020. According to an article published in September 2021 by the Department of Dermatology and Venereology, Bozok and University Faculty of Medicine, Yozgat, Turkey, during the pandemic, the coronavirus had a negative impact on dermatological outpatient clinics as the public was advised not to visit hospitals and outpatient clinics because the primary focus was on providing medical care for COVID-19 patients and controlling the spread of the virus. This study examined the frequency, profile, and diagnostic spectrum of dermatology patients during the pandemic in 2019 to identify the impact of the pandemic. According to a study published in January 2021 by the National Center for Biotechnology Information (NCBI) on the impact of the COVID-19 pandemic on dermatology practice around the world, the COVID outbreak had a negative impact on most dermatology services, with a significant reduction in consultation time spent for chronic patients and a higher risk of missed melanoma and no melanoma skin cancer (NMSC) diagnosis.

Global actinic keratosis market is estimated to be valued at US$ 8,070.0 Mn in 2022 and expected to exhibit a CAGR of 4.7% over the forecast period (2022-2030).

Figure 1: Global Actinic Keratosis Market Share (%) Analysis, By Treatment, 2022

High efficiency of actinic keratosis treatment is expected to drive growth of global actinic keratosis market over the forecast period.

High efficiency of actinic keratosis treatment is expected to be the major factor driving growth of the actinic keratosis market over the forecast period. For instance, according to an article published in the Australian Family Physician journal, a monthly peer-reviewed medical journal, in May 2017, it was estimated that cryosurgery treatment for actinic keratosis has an efficiency between 86% and 99%.

Moreover, a number of treatments for actinic keratosis are available globally, which gives different choices to patients. This is expected to further boost the global actinic keratosis market growth. According to data published by Biofrontera AG Investor Presentation in January 2020, most dermatologists in the U.S. have traditionally preferred cryotherapy for the treatment of actinic keratosis due to more favorable monetary reimbursement whereas dermatologists in Europe have favored topical prescriptions such as fluorouracil, ingenol mebutate, and others due to the lack of reimbursement for procedures such as photodynamic therapy.

Increasing number of product approvals for the treatment of actinic keratosis from regulatory bodies is expected to drive the growth of global actinic keratosis market over the forecast period.

Actinic keratosis market is expected to witness significant growth over the forecast period, owing to increasing focus of market players on gaining product approvals for the treatment of actinic keratosis from regulatory bodies. For instance, in March 2020, Biofrontera AG, a Germany-based pharmaceutical company, announced that it had received approval from the European Commission for the use of its drug Ameluz, in combination with photodynamic therapy for the treatment of adults suffering from actinic keratosis on the extremities and trunk/neck in Europe.

Global Actinic Keratosis Market – Restraints

Global actinic keratosis market growth is expected to be hampered in the near future, owing to side effects of the drugs prescribed for actinic keratosis.

Some of the common side effects of actinic keratosis drugs are:

• Burning or crusting
• Redness or discoloration
• Irritation and pain
• Itching and rash
• Soreness

Some of the serious side effects of actinic keratosis drugs are:

• Severe stomach ache
• Blood in diarrhea
• Vomiting
• Fever and chills
• Severe red skin rashes

Global Actinic Keratosis Market – Region Analysis

On the basis of region, global actinic keratosis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa.

North America is expected to hold a dominant position in the market during the forecast period, owing to increasing number of product approvals for the treatment of actinic keratosis from regulatory bodies by market key players in the region. For instance, in December 2020, Almirall, S.A, a Spain-based pharmaceutical company, announced that it had received the U.S. Food and Drug Administration (FDA) approval for its drug Klisyri (tirbanibulin) indicated for the treatment of actinic keratosis of the face and scalp in adults.

Figure 2: Global Actinic Keratosis Market (US$ Mn), by Region, 2022

Global Actinic Keratosis Market – Competitive Landscape

Major players operating in global actinic kertosis market include Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals, Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals, Inc., Bioforntera AG, Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited.

Detailed Segmentation:

• Global Actinic Keratosis Market, By Treatment:
  • Medication
  • Surgical Procedure
    • Chemical peel
    • Cryosurgery
    • Curettage and desiccation
    • Laser surgery
  • Photodynamic Therapy
  • Combination Therapies
    • Cryosurgery and PDT
    • Cryosurgery and a topical treatment
    • Topical treatments and PD
• Global Actinic Keratosis Market, By End User:
  • Hospitals & Specialty Clinics
  • Homecare
• Global Actinic Keratosis Market, By Region:
  • North America
    • By Treatment:
      • Medication
      • Surgical Procedure
        • Chemical peel
        • Cryosurgery
        • Curettage and desiccation
        • Laser surgery
      • Photodynamic Therapy
      • Combination Therapies
        • Cryosurgery and PDT
        • Cryosurgery and a topical treatment
        • Topical treatments and PD
    • By End User:
      • Hospitals and Specialty Clinics
      • Homecare
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Treatment:
      • Medication
      • Surgical Procedure
        • Chemical peel
        • Cryosurgery
        • Curettage and desiccation
        • Laser surgery
      • Photodynamic Therapy
      • Combination Therapies
        • Cryosurgery and PDT
        • Cryosurgery and a topical treatment
        • Topical treatments and PD
    • By End User:
      • Hospitals and Specialty Clinics
      • Homecare
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Treatment:
      • Medication
      • Surgical Procedure
        • Chemical peel
        • Cryosurgery
        • Curettage and desiccation
        • Laser surgery
      • Photodynamic Therapy
      • Combination Therapies
        • Cryosurgery and PDT
        • Cryosurgery and a topical treatment
        • Topical treatments and PD
      • By End User:
        • Hospitals and Specialty Clinics
        • Homecare
    • By Country:
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Treatment:
      • Medication
      • Surgical Procedure
        • Chemical peel
        • Cryosurgery
        • Curettage and desiccation
        • Laser surgery
      • Photodynamic Therapy
      • Combination Therapies
        • Cryosurgery and PDT
        • Cryosurgery and a topical treatment
        • Topical treatments and PD
    • By End User:
      • Hospitals and Specialty Clinics
      • Homecare
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • By Treatment:
      • Medication
      • Surgical Procedure
        • Chemical peel
        • Cryosurgery
        • Curettage and desiccation
        • Laser surgery
      • Photodynamic Therapy
      • Combination Therapies
        • Cryosurgery and PDT
        • Cryosurgery and a topical treatment
        • Topical treatments and PD
    • By End User:
      • Hospitals and Specialty Clinics
      • Homecare
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Treatment:
      • Medication
      • Surgical Procedure
        • Chemical peel
        • Cryosurgery
        • Curettage and desiccation
        • Laser surgery
      • Photodynamic Therapy
      • Combination Therapies
        • Cryosurgery and PDT
        • Cryosurgery and a topical treatment
        • Topical treatments and PD
    • By End User:
      • Hospitals and Specialty Clinics
      • Homecare
    • By Region:
      • South Africa
      • Central Africa
      • North Africa